Evidence review

ARA-290 for Post-Surgical Nerve Damage: Evidence Review

#peptide#topic
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ara-290-post-surgical-nerve`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ara-290-post-surgical-nerve

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-post-surgical-nerve/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290-post-surgical-nerve/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290-post-surgical-nerve/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290-post-surgical-nerve/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have Post-surgical nerve injury

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: ARA-290 is studied for nerve repair — especially small-fiber and neuropathy models. Nerves degenerate when damaged; ARA-290 research asks whether innervation can regrow.

Why ARA-290 might help you

  1. You are reading about Post-surgical nerve injury — what breaks down matters before any compound name.
  2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
  3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
  4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • ARA-290 → nerve / innervation

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 18
  • Claims tagged human evidence: 9
  • Claims tagged preclinical (animal/lab): 3
  • Claims tagged anecdotal: 26
  • Reddit posts catalogued: 18
  • X posts catalogued: 5
  • Other anecdote sources (YouTube, Instagram, etc.): 1
  • Total sources in chain: 44

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Targeting the innate repair receptor to treat neuropathy (source s1)

Review summarizing human sarcoidosis and T2D trials plus preclinical data.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (source s2)

Primary sarcoidosis SFN trial results.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290... Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (source s3)

T2D neuropathy phase 2 trial.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Discovery of a master regulator of injury and healing (source s5)

Preclinical nerve injury models referenced.

Evidence type: Published research.

ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (source s6)

Preclinical study on spared nerve injury (post-surgical model) showing ARA290 prevents and relieves neuropathic pain long-term.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (source s7)

Details dose-dependent long-term relief of neuropathic pain in spared nerve injury rat model.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Abundance in Patients With Sarcoidosis (source s8)

Ongoing or completed trial on ARA 290 for sarcoid-associated small fiber neuropathy and nerve fiber regeneration.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

The erythropoietin-derived peptide ARA290 reverses established neuritic dystrophy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia (source s9)

Shows ARA290 benefits in diabetic neuropathy model, relevant to nerve damage repair.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury (source s12)

2024 review detailing EPO, ARA290, and CHBP mechanisms and protective effects in peripheral nerve injury models, noting ARA290's neuroprotective role despite short half-life limitations.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Healing Nerve Damage: ARA-290 and BPC-157 (source s13)

Blog post discussing ARA-290 for peripheral nerve regeneration, including post-surgical nerve damage recovery in combination with BPC-157.

Evidence type: Published research.

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury (source s22)

2025 study showing ARA290 (and EPO) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting repair and functional recovery.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury (source s23)

Research article on rat sciatic nerve crush model (relevant to post-injury/surgical nerve damage); ARA290 reduces early inflammation via NLRP3 inhibition in Schwann cells, aiding regeneration.

Evidence type: Published research.

Targeting the innate repair receptor to treat neuropathy (source s25)

2016 review discussing ARA290 (targeting innate repair receptor) in post-surgical neuropathic pain models like spared nerve injury (SNI) and sciatic nerve injury, showing long-term relief of allodynia.

Evidence type: Published research.

ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide (source s26)

Medical overview noting preclinical evidence from surgical nerve injury rat models (e.g., SNI) for potential post-surgical nerve pain relief, while noting lack of human post-surgical trials.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290 Peptide for Neuropathy and Neurodegeneration (source s27)

2025 article summarizing ARA-290 evidence including a new 2025 rat study on microneedle delivery for neuropathy and referencing surgical/preclinical models indirectly via broader neuropathy data.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA-290 Peptide | Inflammation & Nerve Support (source s29)

Clinic medical resource on ARA-290 mechanisms and applications for neuropathic pain and nerve regeneration.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor (source s30)

2026 review of ARA-290 evidence for neuropathic pain and nerve regeneration in SFN and diabetes; discusses preclinical nerve injury models and lack of further trials.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Benefits of ARA290 Peptide: A Simple Guide (source s31)

Blog post on ARA-290 for peripheral nerve damage including injury-related, referencing sarcoidosis studies.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

Effectiveness of ARA-290...My Assessment — Reddit, r/smallfiberneuropathy (source s10)

User anecdote of self-experimenting with ARA-290 for SFN/neuropathy, reporting symptom improvement and nerve healing hints.

Peptide ARA-290 — Reddit, r/neuropathy (source s11)

Reddit discussion thread with user experiences trying ARA-290 for neuropathy symptoms.

ARA290 peptide AND Rebuilder 2407 have changed my life! — Reddit, r/neuropathy (source s14)

User anecdote reporting significant pain relief and improved mobility from ARA-290 for chronic neuropathy symptoms after 8 days of use.

Do I have SFN? ARA-290 helped — Reddit, r/smallfiberneuropathy (source s15)

Anecdotal report of temporary symptom improvement (tingling, temperature awareness) from short-term ARA-290 use for suspected small fiber neuropathy.

ARA-290 peptide — any experience reports? — Reddit, r/neuropathy (source s16)

Post-surgical (back surgery) neuropathy patient reports starting ARA-290 protocol with no side effects so far and optimism based on studies.

ARA-290 peptide — any experience reports? — Reddit, r/neuropathy (source s17)

Positive user report of significant improvement in severe neuropathy after 1 month of ARA-290.

ARA-290 peptide — any experience reports? — Reddit, r/neuropathy (source s18)

Negative experience: painful tingling side effect leading to stopping ARA-290; pain subsided after discontinuation.

ARA-290 for Neuropathic Pain — Reddit, r/smallfiberneuropathy (source s19)

User reports temporary pain relief from ARA-290 requiring ongoing use.

ARA-290 Disc Herniaton & Nerve Pain — Reddit, r/neuropathy (source s20)

User with post-disc herniation (surgical context implied) nerve pain reports no benefits or side effects after short use of ARA-290; planning longer cycle.

ARA-290 Quick Guide: The Erythropoietin-Derived Peptide Targeting Neuropathic Pain and Tissue Protection — Reddit, r/IonPeptideGuide (source s24)

Detailed user guide post discussing ARA-290 mechanisms, clinical trial history, dosing, and nerve repair potential (anecdotal/educational context).

Anybody try ARA-290 peptide for nerve damage? — Reddit, r/Biohackers (source s33)

Positive anecdotal report of significant nerve damage area reduction and symptom improvement from ARA-290 use post-vein ablation procedure (saphenous nerve axonal damage).

ARA 290 14 days in, no relief. — Reddit, r/smallfiberneuropathy (source s34)

Negative user experience reporting no pain relief or symptom improvement after 14 days of ARA-290 (user continued briefly but later discontinued without benefit).

ARA-290, whats your experience? — Reddit, r/neuropathy (source s35)

User reports no effect from 4mg/day ARA-290 for 8 weeks on neuropathy (anecdotal, not advice). Another similar negative report for 60 days.

ARA290 — Reddit, r/neuropathy (source s36)

User tried ARA290 but stopped due to insufficient relief and cost (anecdotal, not advice).

BPC157 — Reddit, r/smallfiberneuropathy (source s37)

Mixed anecdotal outcome: limited overall effect from 2 months ARA290 but some reduction in nerve overfiring symptoms (anecdotal, not advice).

Anyone tried ARA 290 — Reddit, r/neuropathy (source s41)

User reports trying 4mg daily ARA-290 (anecdotal) with uncertain effects on neuropathy alongside other treatments; no clear positive or negative outcome detailed for post-surgical nerve issues.

What people say on X

X post on ARA-290 for nerve pain — X (source s21)

Positive anecdotal report of ARA-290 helping nerve pain in neck and shoulders.

X post about back surgery and ARA-290 — X (source s38)

Positive anecdotal report of ARA-290 helping post-back surgery nerve issues (anecdotal, not advice).

X post on running ARA-290 — X (source s39)

Anecdotal dosing and stacking advice for nerve repair (anecdotal, not advice).

X post personal experience ARA-290 — X (source s40)

Positive anecdotal report on ARA-290 for nerve repair and inflammation (anecdotal, not advice).

X post by @peptidepirate — X (source s44)

User considering ARA-290 for personal nerve damage (anecdotal intent); no outcome reported.

What we do not know

  1. There is a lack of data on the comparative efficacy of ARA-290 against standard treatments for post-surgical nerve damage.

Safety and limits

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

Peptide components (collapsible embeds)

ARA-290: Nerve Repair Peptide · nerve / innervation · ara-290
{
  "peptide": "ara-290",
  "regenerative_layer": "nerve / innervation",
  "targets_this_degeneration": "Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.",
  "proposed_regeneration": "Studied for nerve repair and small-fiber regeneration in neuropathy models.",
  "evidence_in_ledger": {
    "human_claims": 13,
    "preclinical_claims": 1,
    "anecdote_claims": 45,
    "studies_catalogued": 21
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/ara-290"
}

Regeneration vs degeneration — where this fits Nerves break down after injury or disease. Small fiber neuropathy is one case where breakdown outruns repair. Most drugs used for neuropathy reduce pain signals without changing nerve structure. ARA-290 is studied for the repair side: whether damaged small nerves can regro…

Full ara-290 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Nerve damage / repair · condition map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpARA-290: Nerve Repair Peptide · 13 humanARA-290 for Diabetic Neuropathy: Human Trial Data · 12 humanARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe… · 8 humanARA-290 × Stimulant-driven insomnia
Evidence · 44 sources · swipe →chain 47a68756fca8 · verify chain · provenance
1 / 44
Evidence ledger 48 · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
Blog post on ARA-290 for peripheral nerve damage including injury-related, referencing sarcoidosis studies.
sources: s31
preclinical
Details dose-dependent long-term relief of neuropathic pain in spared nerve injury rat model.
sources: s7
system
Combinatorial mapping (transparent): ara-290 vs post-surgical-nerve — regen=0.888, degen=0.83, Δ=0.057. Method: layer_relevance(0.95) × evidence_factor(0.85); catalog.degen_score for Post-surgical nerve injury.
system
ARA-290 for Post-Surgical Nerve Damage: Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
39 more ranked claims
human0.22downweighted
Human trials in sarcoidosis SFN showed symptom improvement and increased corneal nerve fiber density after 28 days of ARA-290.
grok/4.3-populate
Direct evidence of structural nerve fiber changes in humans
sources: s1, s2
human0.22downweightedlow confidence
Human trial in type 2 diabetes neuropathy showed improved neuropathic symptoms and CNFD increase in subgroup.
grok/4.3-populate
Additional human data on symptom and structural outcomes
sources: s3
human0.22
ARA-290 activates IRR to promote anti-inflammatory and repair pathways rather than symptomatic pain masking.
grok/4.3-populate
Distinguishes repair mechanism from suppression
sources: s1
human0.22
Commercial vendors and clinics market this compound (9 commercial/clinic sources catalogued) — marketing material, not evidence.
commercial vendors
Collapsed 13 duplicate marketing claims
sources: s6, s24, s26, s27, s28, s29, s30, s1, s8
human0.22low confidence
Ongoing or completed trial on ARA 290 for sarcoid-associated small fiber neuropathy and nerve fiber regeneration.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
human0.22
2024 review detailing EPO, ARA290, and CHBP mechanisms and protective effects in peripheral nerve injury models, noting ARA290's neuroprotective role despite short half-life limitations.
grok/grok-4.3
Materialized from orphan source s12 by ledger repair
sources: s12
human0.22
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
human0.22
There is a lack of data on the comparative efficacy of ARA-290 against standard treatments for post-surgical nerve damage.
kimi-collaborator
This claim addresses a specific gap in knowledge regarding the comparative effectiveness of ARA-290, which is important for understanding its potential role in clinical practice.
sources: s1
preclinical0.22
Shows ARA290 benefits in diabetic neuropathy model, relevant to nerve damage repair.
grok/grok-4.3
Materialized from orphan source s9 by ledger repair
sources: s9
preclinical0.22
2025 study showing ARA290 (and EPO) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting repair and functional recovery.
grok/grok-4.3
Materialized from orphan source s22 by ledger repair
sources: s22
mechanistic0.22low confidence
Rat models of sciatic nerve injury show reduced allodynia and nerve repair effects with ARA-290.
grok/4.3-populate
Provides mechanistic mapping to surgical injury models
sources: s5
mechanistic0.22
While the study mentioned in claim c1 shows increased corneal nerve fiber density, it does not necessarily imply direct nerve repair in the context of post-surgical nerve damage, as the study was conducted in sarcoidosis patients, which may have different underlying mechanisms.
kimi/moonshot-v1-8k (adversary)
This counter-evidence challenges the direct applicability of the findings from claim c1 to the context of post-surgical nerve damage, highlighting the need for more specific evidence in the surgical context.
mechanistic0.22
While the human trial mentioned in claim c2 showed improved neuropathic symptoms and CNFD increase in a subgroup, the applicability of these findings to post-surgical nerve damage specifically is uncertain due to differences in patient populations and study context.
kimi/moonshot-v1-8k (adversary)
This counter-evidence challenges the direct applicability of the findings from claim c2 to the context of post-surgical nerve damage, highlighting the need for more specific evidence in the surgical context.
anecdotal0.22
User anecdote of self-experimenting with ARA-290 for SFN/neuropathy, reporting symptom improvement and nerve healing hints.
grok/grok-4.3
Materialized from orphan source s10 by ledger repair
sources: s10
anecdotal0.22
Reddit discussion thread with user experiences trying ARA-290 for neuropathy symptoms.
grok/grok-4.3
Materialized from orphan source s11 by ledger repair
sources: s11
anecdotal0.22
User anecdote reporting significant pain relief and improved mobility from ARA-290 for chronic neuropathy symptoms after 8 days of use.
grok/grok-4.3
Materialized from orphan source s14 by ledger repair
sources: s14
anecdotal0.22
Anecdotal report of temporary symptom improvement (tingling, temperature awareness) from short-term ARA-290 use for suspected small fiber neuropathy.
grok/grok-4.3
Materialized from orphan source s15 by ledger repair
sources: s15
anecdotal0.22low confidence
Post-surgical (back surgery) neuropathy patient reports starting ARA-290 protocol with no side effects so far and optimism based on studies.
grok/grok-4.3
Materialized from orphan source s16 by ledger repair
sources: s16
anecdotal0.22low confidence
Positive user report of significant improvement in severe neuropathy after 1 month of ARA-290.
grok/grok-4.3
Materialized from orphan source s17 by ledger repair
sources: s17
anecdotal0.22
Negative experience: painful tingling side effect leading to stopping ARA-290; pain subsided after discontinuation.
grok/grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
anecdotal0.22
User reports temporary pain relief from ARA-290 requiring ongoing use.
grok/grok-4.3
Materialized from orphan source s19 by ledger repair
sources: s19
anecdotal0.22
User with post-disc herniation (surgical context implied) nerve pain reports no benefits or side effects after short use of ARA-290; planning longer cycle.
grok/grok-4.3
Materialized from orphan source s20 by ledger repair
sources: s20
anecdotal0.22
Positive anecdotal report of ARA-290 helping nerve pain in neck and shoulders.
grok/grok-4.3
Materialized from orphan source s21 by ledger repair
sources: s21
anecdotal0.22
Instagram reel by foot/ankle surgeon recommending ARA-290 specifically for post-operative nerve pain and nerve injury.
grok/grok-4.3
Materialized from orphan source s32 by ledger repair
sources: s32
anecdotal0.22
Anecdotal reports of ARA-290's effectiveness come from various individuals on platforms like Reddit.
kimi-collaborator
Identifying the source of anecdotal claims is important for transparency and to understand the nature of the evidence provided by such claims.
sources: s10
anecdotal0.22
Anecdotal reports from patients on online forums suggest ARA-290 may provide relief for post-surgical nerve pain, but these are not systematically collected or verified.
kimi-collaborator
This claim fills the slot for anecdotal claims, acknowledging the existence of patient experiences that are not part of formal clinical studies.
sources: s10
anecdotal0.22
A Reddit user provides their personal assessment regarding the effectiveness of ARA-290.
gemini-collaborator
Captures an additional anecdotal perspective from the provided sources, fulfilling the instruction to 'Name who claims what from anecdotes if missing.'
sources: s10
anecdotal0.22
Positive anecdotal report of significant nerve damage area reduction and symptom improvement from ARA-290 use post-vein ablation procedure (saphenous nerve axonal damage).
grok-4.3
Materialized from orphan source s33 by ledger repair
sources: s33
anecdotal0.22low confidence
Negative user experience reporting no pain relief or symptom improvement after 14 days of ARA-290 (user continued briefly but later discontinued without benefit).
grok-4.3
Materialized from orphan source s34 by ledger repair
sources: s34
anecdotal0.22
User reports no effect from 4mg/day ARA-290 for 8 weeks on neuropathy (anecdotal, not advice). Another similar negative report for 60 days.
grok-4.3
Materialized from orphan source s35 by ledger repair
sources: s35
anecdotal0.22
User tried ARA290 but stopped due to insufficient relief and cost (anecdotal, not advice).
grok-4.3
Materialized from orphan source s36 by ledger repair
sources: s36
anecdotal0.22
Mixed anecdotal outcome: limited overall effect from 2 months ARA290 but some reduction in nerve overfiring symptoms (anecdotal, not advice).
grok-4.3
Materialized from orphan source s37 by ledger repair
sources: s37
anecdotal0.22low confidence
Positive anecdotal report of ARA-290 helping post-back surgery nerve issues (anecdotal, not advice).
grok-4.3
Materialized from orphan source s38 by ledger repair
sources: s38
anecdotal0.22
Anecdotal dosing and stacking advice for nerve repair (anecdotal, not advice).
grok-4.3
Materialized from orphan source s39 by ledger repair
sources: s39
anecdotal0.22
Positive anecdotal report on ARA-290 for nerve repair and inflammation (anecdotal, not advice).
grok-4.3
Materialized from orphan source s40 by ledger repair
sources: s40
anecdotal0.22low confidence
User reports trying 4mg daily ARA-290 (anecdotal) with uncertain effects on neuropathy alongside other treatments; no clear positive or negative outcome detailed for post-surgical nerve issues.
grok-4.3
Materialized from orphan source s41 by ledger repair
sources: s41
anecdotal0.22
Anecdotal comment on ARA-290 for SFN/EM (related nerve pain): temporary relief in some, loses efficacy, best for central sensitization; suggests short trial from peptide sources (anecdotal, not advice).
grok-4.3
Materialized from orphan source s42 by ledger repair
sources: s42
anecdotal0.22
Discussion of ARA-290 for neuropathic pain including potential nerve support; general positive research mention but no specific user outcomes or post-surgical anecdotes here.
grok-4.3
Materialized from orphan source s43 by ledger repair
sources: s43
anecdotal0.22
User considering ARA-290 for personal nerve damage (anecdotal intent); no outcome reported.
grok-4.3
Materialized from orphan source s44 by ledger repair
sources: s44
Low-confidence / auto-generated 4
speculative0.12
No human trials have tested ARA-290 in post-surgical nerve damage.
grok/4.3-populate
Clarifies evidence gap for the target population
sources: s4
speculative0.12low confidence
Blog post discussing ARA-290 for peripheral nerve regeneration, including post-surgical nerve damage recovery in combination with BPC-157.
grok/grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
speculative0.12
Research article on rat sciatic nerve crush model (relevant to post-injury/surgical nerve damage); ARA290 reduces early inflammation via NLRP3 inhibition in Schwann cells, aiding regeneration.
grok/grok-4.3
Materialized from orphan source s23 by ledger repair
sources: s23
speculative0.12
2016 review discussing ARA290 (targeting innate repair receptor) in post-surgical neuropathic pain models like spared nerve injury (SNI) and sciatic nerve injury, showing long-term relief of allodynia.
grok/grok-4.3
Materialized from orphan source s25 by ledger repair
sources: s25
Model swipes · 21 from 6 models · swipe →verify
1 / 21
grok/grok-4.3writer
redraft2026-06-29 08:55
ARA-290 for Post-Surgical Nerve Damage: Evidence Review · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "ara-290-for-post-surgical-nerve-damage",
  "title": "ARA-290 for Post-Surgical Nerve Damage: Evidence Review",
  "body": "## Overview\n\nARA-290 (cibinetide) is an 11-amino-acid peptide selective agonist of the innate repair receptor (IRR), a heteromer of EPO receptor and β-common receptor subunits upregulated after tissue injury. Activation promotes anti-inflammatory and tissue-repair signaling without hematopoietic effects.\n\n## Human Clinical Data\n\nTwo randomized, double-blind, placebo-controlled trials in small-fiber neuropathy (SFN) associated with sarcoidosis reported symptom improvement on the Small Fiber Neuropathy Screening List after 28 days of 4 mg daily subcutaneous ARA-290, plus increased corneal nerve fiber density (CNFD) measured by in vivo confocal microscopy in one trial (human tier). A phase 2 trial in type 2 diabetes with painful neuropathy showed improved neuropathic symptoms on PainDetect questionnaire, HbA1c reduction, and CNFD increase in a subgroup with baseline reduction (human tier). No serious adverse effects linked to erythropoiesis were observed.\n\n## Relevance to Post-Surgical Nerve Damage\n\nNo human trials have evaluated ARA-290 specifically in post-surgical nerve injury or compression (no human data). Preclinical rat models of sciatic nerve crush or spared nerve injury demonstrate reduced allodynia and promotion of nerve repair
f9fe221069229e26
grok-4.3source_hunt
sources2026-06-29 10:37
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
4 source(s) added
1dc51f4e46c70fd2
grok-4.3source_hunt
sources2026-06-29 10:37
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
4 source(s) added
965e49e5e62bd3e8
grok-4.3source_hunt
sources2026-06-29 10:38
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
3 source(s) added
283c77014ca0e2ca
grok-4.3source_hunt
sources2026-06-29 10:38
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
3 source(s) added
b9720ebcfe0dc508
grok-4.3source_hunt
sources2026-06-29 10:39
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
3 source(s) added
b7ea57830126d9f9
grok-4.3source_hunt
sources2026-06-29 10:39
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
3 source(s) added
8f252dafa49e1b60
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
{"materialized":0,"before":[],"after":[]}
4003ea03f8e78629
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
{"materialized":0,"before":[],"after":[]}
7eceb18d104ba57e
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
{"materialized":0,"before":[],"after":[]}
74ceccb5cd402468
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
{"materialized":0,"before":[],"after":[]}
a6c3b125374f7ffa
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
{"materialized":0,"before":[],"after":[]}
e147aa1b35ba6e5a
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:25
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
I am adding explicit gaps in knowledge (what_is_unknown) and identifying anecdotal claimants (who_claims_what) to fulfill the instructions.
93944e89829c422b
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:26
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
I am adding explicit gaps in knowledge and naming anecdotal claimants as instructed. I am not Grok because I am adding new claims that were not present in the initial topology but are required to fulfill the slots 'what_is_unknown' and 'who_claims_what'.
91d053ff0d5e71b1
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 14:53
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
I added two tier-honest claims to fill gaps in the ledger. One claim captures an additional anecdotal perspective from a provided source, addressing the 'who_claims_what' slot. The second claim clarifies the specific focus of a human clinical trial, contributing to the 'what_is_known' slot. I am not Grok because I strictly adhered to the provided topology and instructions, using only the specified source IDs and focusing on explicit gaps in the ledger's representation of the given information.
44ee6984329a6460
grok/grok-4.3editor
synthesize_body2026-06-29 14:54
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
## Regeneration vs degeneration — where this fits
The body breaks down tissue and builds it back at the same time. When breakdown outruns repair after surgery, nerves can stay damaged and signals stay active. ARA-290 is studied for the repair side of this balance in nerve tissue.

## What it is
ARA-290 is a short chain of amino acids. It comes from the structure of erythropoietin but does not raise red blood cells. Research focuses on its effect on small nerve fibers and neuropathic pain after injury.

## How it works
It binds a receptor called the innate repair receptor. Binding turns on signals that lower inflammation in nerve-support cells. It also reduces activation of NLRP3 inflammasome in Schwann cells after nerve crush. These steps are shown in rat models.

## Why it would work (logic chain)
If nerve injury causes ongoing inflammation, then lowering that inflammation could allow regrowth signals to dominate. If regrowth signals dominate, then small nerve fiber density can rise and pain sensitivity can fall. Rat studies test this chain after surgical-type nerve cuts. Human sarcoidosis trials test the same chain in small fiber loss.

## Why people take it
People with ongoing nerve pain after surgery or with small fiber neuropathy look for options that target repair rather than only masking pain. They read trial summaries and animal data that show reduced allodynia and incr
a698b6857e245491
grok-4.3source_hunt
sources2026-06-29 15:57
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
2 source(s) added
a7a31d861cb9a38b
grok-4.3source_hunt
sources2026-06-29 18:01
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
6 source(s) added
f392672e92ad30eb
grok-4.3source_hunt
sources2026-06-29 18:02
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve
it output
4 source(s) added
62e0e5565f6847fb
fill-slotsclaim_post
claim2026-06-29 20:57
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve c59
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
6cabf54cdba018e0
fill-slotsclaim_post
claim2026-06-29 20:57
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-post-surgical-nerve c59
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
d717a3a1c2069223

Related research

Nerve damage / repair · condition map

Open evidence map →
ARA-290: Nerve Repair Peptideembedded in this articleara-290ARA-290 × Stimulant-driven insomniaara-290-adderall-insomniaBenzo Withdrawalara-290-benzo-withdrawalARA 290 for Benzodiazepinesara-290-benzodiazepinesARA 290 for Brain Fogara-290-brain-fogARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe…ara-290-carpal-tunnelARA 290 for Chemoara-290-chemoChemo Neuropathyara-290-chemo-neuropathyARA 290 for Cognitionara-290-cognitionARA 290 for Corticosteroidsara-290-corticosteroids
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask ara-290-post-surgical-nerve claim c59 · paste includes §SELF
What does the ledger say about this (human tier): "Commercial vendors and clinics market this compound (9 commercial/clinic sources catalogued) — marketing material, not evidence."?
ask ara-290-post-surgical-nerve claim c6 · paste includes §SELF
What does the ledger say about this (human tier): "Blog post on ARA-290 for peripheral nerve damage including injury-related, referencing sarcoidosis studies."?
ask ara-290-post-surgical-nerve claim c31 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask ara-290-post-surgical-nerve claim c37 · paste includes §SELF
What does the ledger say about this (preclinical tier): "Details dose-dependent long-term relief of neuropathic pain in spared nerve injury rat model."?
ask ara-290-post-surgical-nerve claim c7 · paste includes §SELF
What does the ledger say about this (preclinical tier): "Shows ARA290 benefits in diabetic neuropathy model, relevant to nerve damage repair."?
ask ara-290-post-surgical-nerve claim c9 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User anecdote of self-experimenting with ARA-290 for SFN/neuropathy, reporting symptom improvement and nerve healing hin"
ask ara-290-post-surgical-nerve source s10 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Reddit discussion thread with user experiences trying ARA-290 for neuropathy symptoms."
ask ara-290-post-surgical-nerve source s11 · paste includes §SELF
ara-290-post-surgical-nerve · posted 2026-06-29 · updated 2026-06-29 · 26 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 26 model passes · 19087 tokens · $0 · 7 models
chain head e1c628a1bdef3abf
write grok/grok-4.3 · 2026-06-29 08:55 · 0 tok · bb03d2f586b1
sources grok-4.3 · 2026-06-29 10:37 · 0 tok · 61308dadff4a
sources grok-4.3 · 2026-06-29 10:37 · 0 tok · 13e288d44d04
sources grok-4.3 · 2026-06-29 10:38 · 0 tok · d2ff9eac7a01
sources grok-4.3 · 2026-06-29 10:38 · 0 tok · a0a6404b76b8
sources grok-4.3 · 2026-06-29 10:39 · 0 tok · c33cbfcc8df3
sources grok-4.3 · 2026-06-29 10:39 · 0 tok · 3b8f080194c9
repair system/audit-repair · 2026-06-29 12:48 · 0 tok · 5d65fc3ccf72
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · a43d43fa0e72
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · 071782123699
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · 241c14224282
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · 0123aaba3b88
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · f86f05258854
repair system/audit-repair · 2026-06-29 12:48 · 0 tok · 77d0bbbe6614
repair system/audit-repair · 2026-06-29 13:23 · 0 tok · 68243f4b8414
repair system/audit-repair · 2026-06-29 13:23 · 0 tok · b3f2b18521bd
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:25 · 3605 tok · 8fb0194acf94
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:26 · 3701 tok · 329d75f2b256
collaborate gemini/gemini-2.5-flash · 2026-06-29 14:53 · 3283 tok · 1a154845e38c
synthesize_body grok/grok-4.3 · 2026-06-29 14:54 · 8498 tok · 2645bdb82963
sources grok-4.3 · 2026-06-29 15:57 · 0 tok · c243a2b1f25f
sources grok-4.3 · 2026-06-29 18:01 · 0 tok · 03d3169c696c
sources grok-4.3 · 2026-06-29 18:02 · 0 tok · 5336b3db4b7e
repair repair · 2026-06-29 19:43 · 0 tok · ba89cbe05a6f
claim fill-slots · 2026-06-29 20:57 · 0 tok · 6d9f0c86cb56
claim fill-slots · 2026-06-29 20:57 · 0 tok · e1c628a1bdef
verify chain →
Live ledger · 46 payloads · 10 turns
recent activity · inspect
webhook_in blooio · 2026-06-29 21:28
webhook_in blooio · 2026-06-29 21:28
PROTOCOL_RUN dispatch · 2026-06-29 21:28 · t_l6kgxw6f
PROTOCOL_RUN dispatch · 2026-06-29 21:28 · t_l6kgxw6f
webhook_in blooio · 2026-06-29 21:28
webhook_in blooio · 2026-06-29 21:28
view full ledger & cards →
REST + ledger
read GET /api/articles/ara-290-post-surgical-nerve · GET /api/articles/ara-290-post-surgical-nerve?format=post (the editable body)
create/replace POST /api/articles/ara-290-post-surgical-nerve · PUT /api/articles/ara-290-post-surgical-nerve (replace, keeps revision) · PATCH /api/articles/ara-290-post-surgical-nerve (merge)
delete DELETE /api/articles/ara-290-post-surgical-nerve
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/ara-290-post-surgical-nerve/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/ara-290-post-surgical-nerve/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim ara-290-post-surgical-nerve|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →